Semaglutide is a medication used for the treatment of type 2 diabetes. The product belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists, which increase the body's insulin production, reduce the amount of glucose produced by the liver, and slow down digestion.
Semaglutide is available as a once-weekly injection. It is used in combination with diet and exercise to control blood sugar levels in people with type 2 diabetes. The drug has been shown to effectively reduce blood sugar levels, lower the risk of cardiovascular events, and promote weight loss.
In addition to its use in diabetes, Semaglutide has also been approved for use in the treatment of obesity. In this context, it is used at a higher dose than in diabetes and has been shown to be effective in stimulating weight loss.
Semaglutide is available in a single-dose, pre-filled pen for subcutaneous injection. The dose and frequency of Semaglutide may vary depending on the indication for use.
Semaglutide should be administered as a subcutaneous injection into the abdomen, thigh, or upper arm, and the injection site should be rotated to avoid repeated injections in the same area.
Semaglutide is a relatively new medication, and its patent is held by its manufacturer, Novo Nordisk. Semaglutide is protected by various patents in different countries. Novo Nordisk, the manufacturer of Semaglutide, has multiple patents covering the drug's formulation, methods of use, and other aspects of its production and distribution.
In the USA, the FDA approved the first Semaglutide patent in 2018, which is set to expire in 2035. Other patents related to Semaglutide are also set to expire between 2024 and 2038.
In Europe, the European Medicines Agency (EMA) approved Semaglutide in 2018, and it is protected by multiple patents there. The main European patent for Semaglutide expires in 2033, with other related patents set to expire between 2024 and 2034.
Semaglutide medication is available in various countries worldwide, including the United States, Canada, European Union member countries, Australia, New Zealand, Japan, China, and many others.
Semaglutide is manufactured by Novo Nordisk, a Danish pharmaceutical company. Novo Nordisk markets Semaglutide under several brand names, including Ozempic, Rybelsus, and Wegovy.
Ozempic product is indicated for the treatment of type 2 diabetes and is available in 0.5 mg and 1.0 mg single-dose pre-filled pens for subcutaneous injection.
Rybelsus is also indicated for the treatment of type 2 diabetes and is available in tablet form for oral administration. The tablet is available in several strengths, including 3 mg and 14 mg.
Wegovy is indicated for chronic weight management and is available in a 2.4 mg single-dose pre-filled pen for subcutaneous injection.
The wholesale price of Semaglutide can vary depending on the specific formulation, strength, and country of purchase. In the United States, as of 2022, the wholesale acquisition cost (WAC) for a single 1 mg dose of Ozempic (Semaglutide) is approximately $850 USD. The WAC for a monthly supply of Rybelsus (Semaglutide tablets) ranges from $898 USD to $1,301 USD, depending on the strength. The WAC for a monthly supply of Wegovy (Semaglutide) is approximately $1,439 USD.
Pipelinepharma is an online platform designed to facilitate B2B transactions in the pharmaceutical industry. Its primary function is to assist buyers in locating trustworthy Semaglutide manufacturers and dossier owners from around the globe.
By connecting them with verified suppliers, Pipelinepharma simplifies the process of negotiating and obtaining competitive pricing.
Pipelinepharma lists over 70,000 generic products from various manufacturers, which can be conveniently accessed in the marketplace using helpful filters.
Currently, no generic versions of Semaglutide are available worldwide, but some manufacturing companies are getting ready for the patent expiration. You can check them on the Pipelinepharma marketplace. Sign up on Pipelinepharma for free and browse all available Semaglutide or alternative products for the treatment of type 2 diabetes.